melanoma

Seres Therapeutics and Nestlé Health Science Announce FDA Approval of VOWST™ (fecal microbiota spores, live-brpk) for Prevention of Recurrence of C. difficile Infection in Adults Following Antibacterial Treatment for Recurrent CDI

Industry

Seres Therapeutics and Nestlé Health Science Announce FDA Approval of VOWST™ for Prevention of Recurrence of C. difficile Infection in Adults Following Antibacterial Treatment for Recurrent CDI

First and only FDA-approved orally administered microbiota-based therapeutic, validating Seres’ microbiome platform –

Industry

Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies

The VE303 study would be the first pivotal Phase 3 study of a therapeutic candidate based on a defined bacterial consortium, which Vedanta is pioneering as a next-generation approach to…

Microbiotica Announces Clinical Trial Collaboration with MSD to Evaluate MB097 in Combination with KEYTRUDA® (pembrolizumab) in a Phase 1b Clinical Trial in Melanoma

Industry

Microbiotica Announces Clinical Trial Collaboration with MSD to Evaluate MB097 in Combination with KEYTRUDA® in a Phase 1b Clinical Trial in Melanoma

The bacterial strains in MB097 were identified by analysing the microbiome of patients in multiple studies of ICIs in melanoma.

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.

MicrobiomePost

MicrobiomeHUB

Via Podgora 12/A, 20122, Milan, Italy – VAT: IT05299040963

Read MicrobiomePost’s Privacy Policy

This communication is only intended for business-to-business and health care professionals.
This communication is not intended for consumers of final consumer goods.
Nothing on this page is meant to be perceived as an approved claim.